Y-90 M5A

N/A

Report date: 2025/09/11 20:00:08
NME

Base Information

Drug NameY-90 M5A
Drug Alias Name90Y-DOTA-M5Ayttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
ClassificationRadiation-emitting products > Nuclides > Yttrium > 90YRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsCarcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsLiver NeoplasmsRectal NeoplasmsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteCity Of Hope National Medical Center
Active IndicationsN/A
Inactive IndicationsLiver NeoplasmsRectal NeoplasmsColonic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A